Metabolic HealthGLP-1 Drugs May Restore Eye Surface Health While Reshaping Facial Anatomy
GLP-1 receptor agonists like semaglutide and liraglutide — best known for diabetes and weight loss — appear to have meaningful effects on the eye's surface. Preclinical studies show these drugs reduce inflammation and fibrosis in the lacrimal gland, improve tear production, accelerate corneal healing, and support nerve regeneration. In humans, early observational data suggest lower rates of dry eye disease among GLP-1 users. However, these same drugs may cause periocular fat loss and structural changes around the eyelids that could impair blinking and tear film stability. This review frames the overall picture as a dual story: biological restoration at the tear-producing and corneal level, alongside anatomical remodeling of the tissue scaffolding around the eye — with the restoration side currently having stronger evidence.
